Healius schedules October 22 AGM: analysts target Healius stock at AUD 0.55

Published on 10/20/2026 at 21:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Healius AGM is October 22 after EBIT reached AUD 30.20 million. Healius stock costs EUR 0.24 on October 20, 2026, while ASX last traded at AUD 0.39.

AGM and financial markers

Healius scheduled its October 22, 2026 annual general meeting, while the average analyst target stood at AUD 0.55.
Underlying revenue rose 2.10 percent to AUD 1.37 billion in fiscal year 2026, and underlying EBIT reached AUD 30.20 million.
Healius stock costs EUR 0.24 at Lang & Schwarz on October 20, 2026 at 9:45 p.m. CEST; ASX was up 2.63 percent at AUD 0.39.
Australian Clinical Labs traded at AUD 2.90 with a P/E of 23.52, while Sonic Healthcare traded at AUD 18.73 with a P/E of 15.23.

Healius, AU0000033359, Illustration mit AI erstellt.

Healius scheduled its October 22, 2026 annual general meeting in an announcement dated September 16, according to SmallCapData. Simply Wall St listed an average AUD 0.55 target from 10 analysts in its October 17, 2026 update. Yahoo Finance reported that Healius delivered fiscal year 2026 underlying revenue of AUD 1.37 billion, up 2.10 percent, while underlying EBIT rose to AUD 30.20 million from AUD 17.10 million.

At Lang & Schwarz, Healius stock was trading at EUR 0.24 on October 20, 2026 at 9:45 p.m. CEST. The ASX quote was AUD 0.39 at 4:10 p.m. AEDT, up 2.63 percent from AUD 0.38.

AGM date meets an improving result

The annual meeting comes after a year of improved operating earnings but continued pressure below the EBIT line. Underlying EBITDA increased 8.10 percent to AUD 258.60 million in fiscal year 2026, according to the earnings-call transcript, while reported net debt reached AUD 32.80 million at year-end.

Healius said pathology revenue increased 1.80 percent in fiscal year 2026. Agilex revenue rose 14.10 percent to AUD 43.60 million, although Healius agreed in September to sell the business for AUD 160.00 million, a transaction that changes the group's operating mix.

Where the ASX price sits

Healius last traded between AUD 0.38 and AUD 0.39 on October 20, 2026. Its 52-week ASX range was AUD 0.30 to AUD 1.07, leaving the latest quote AUD 0.68, or 63.55 percent, below the high. Market capitalization stood at AUD 283.20 million and volume was 438,080 shares.

Valuation and upcoming dates

The average analyst target of AUD 0.55 is 41.03 percent above the ASX price of AUD 0.39. The AGM on October 22 is the next scheduled corporate date, while the latest reported results cover fiscal year 2026, ended June 30, 2026.

Comparison with peers

Healius (ASX, AUD): up 2.63 percent, market capitalization AUD 283.20 million. Australian Clinical Labs (ASX, AUD): up 1.05 percent, P/E 23.52, market capitalization AUD 540.90 million. Sonic Healthcare (ASX, AUD): up 1.08 percent, P/E 15.23, market capitalization AUD 9.30 billion.

Stock position before the AGM

For investors, the immediate contrast is clear: Healius improved underlying EBIT from AUD 17.10 million to AUD 30.20 million, yet its ASX quote remains well below the AUD 1.07 52-week high. The AGM will provide the next scheduled setting for management to address margins, debt and the post-Agilex portfolio.

Healius stock was trading at EUR 0.24 at Lang & Schwarz on October 20, 2026 at 9:45 p.m. CEST, while its ASX quote was AUD 0.39 and up 2.63 percent from AUD 0.38. The further course of trading is shown by the continuously updated real-time quote of Healius stock.